维生素B12水平对叶酸治疗与CKD进展关联的影响:一项叶酸干预试验的事后分析
本研究为CSPPT肾脏病亚组的事后分析,纳入1374例轻中度CKD高血压患者,随机接受依那普利联合叶酸或单用依那普利。中位治疗4.4年,基线B12≥248pmol/L者联合叶酸显著降低CKD进展风险(OR 0.17),而B12<248pmol/L者无显著差异,交互作用P=0.001。
要点
- 基线B12≥248pmol/L者,联合叶酸降低CKD进展风险83%(OR 0.17)。
- 基线B12<248pmol/L者,联合叶酸对CKD进展无显著影响(OR 1.21)。
- B12水平与叶酸治疗的交互作用显著(P=0.001)。
核心结论
- 在轻中度CKD高血压患者中,基线B12水平较高者接受叶酸治疗与CKD进展风险降低相关。
- 基线B12水平较低(代谢性B12缺乏)者未见叶酸治疗的显著获益。
研究设计与样本
- CSPPT肾脏病亚组的事后分析,纳入1374例轻中度CKD高血压成人,基线有B12测量。
- 双盲随机每日接受依那普利10mg联合叶酸0.8mg或单用依那普利10mg,中位治疗4.4年。
主要发现
- 基线B12≥248pmol/L者,联合叶酸组主要结局OR为0.17(95%CI 0.07-0.40)。
- 基线B12<248pmol/L者,联合叶酸组主要结局OR为1.21(95%CI 0.51-2.85)。
- B12水平与叶酸治疗的交互作用P=0.001。
- 平均基线eGFR为86.1±20.5 mL/min/1.73m2。
关键数值与推荐
- 主要结局定义为CKD进展:基线eGFR≥60者eGFR下降≥30%且降至<60mL/min/1.73m2,或基线eGFR<60者eGFR下降≥50%,或肾衰竭。
- 基线B12分层界值为248pmol/L。
临床怎么用
- 对轻中度CKD高血压患者,可考虑检测基线B12水平以识别叶酸治疗可能获益的人群。
- B12水平较低者补充叶酸对延缓CKD进展的获益不明确。
局限性
- 本研究为事后分析,事件发生率低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: In populations with folic acid fortification or supplementation, the main nutritional determinant of total homocysteine levels is vitamin B12 (B12) status. We aimed to evaluate the modifying effect of B12 levels on the association between folic acid treatment and chronic kidney disease (CKD) progression. STUDY DESIGN: A post hoc analysis of an interventional trial. SETTING & PARTICIPANTS: This is a post hoc analysis of 1,374 hypertensive adults with mild to moderate CKD and B12 measurements at baseline from the kidney disease substudy of the China Stroke Primary Prevention Trial (CSPPT), conducted in 20 communities in Jiangsu province in China, a region with low folate consumption. INTERVENTIONS: Assignments to a double-blinded daily treatment of enalapril, 10mg, and folic acid, 0.8mg; or enalapril, 10mg, alone. OUTCOMES: The primary outcome was progression of CKD (defined as a decrease in estimated glomerular filtration rate [eGFR] ≥ 30% and to a level of<60mL/min/1.73m2 if baseline eGFR was≥60mL/min/1.73m2; or a decrease in eGFR≥50% if baseline eGFR was<60mL/min/1.73m2; or kidney failure). RESULTS: Mean baseline eGFR in this study was 86.1±20.5 (SD) mL/min/1.73m2. Median treatment duration was 4.4 years. Among participants with higher baseline B12 levels (≥248pmol/L), compared to enalapril alone, enalapril-folic acid treatment was associated with an 83% reduction in the odds of the primary outcome (OR, 0.17; 95% CI, 0.07-0.40). However, among those with baseline B12 levels<248pmol/L (metabolic B12 deficiency), there was no significant group difference in the primary outcome (OR, 1.21; 95% CI, 0.51-2.85). The interaction between B12 level and folic acid treatment was significant (P = 0.001). LIMITATIONS: The analysis is post hoc and event rate is low. CONCLUSIONS: Folic acid treatment was associated with a greater reduction in the odds of CKD progression among patients with mild to moderate CKD and higher B12 levels. FUNDING: Government funding (National Key Research and Development Program of China).
引用
- Li Y, Spence JD, Wang X, et al. Effect of Vitamin B12 Levels on the Association Between Folic Acid Treatment and CKD Progression: A Post Hoc Analysis of a Folic Acid Interventional Trial. Am J Kidney Dis. 2019. PMID: 31629573. doi:10.1053/j.ajkd.2019.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。